PDGFRβ was proposed as a possible pharmacological target in epilepsy and the PDGFRβ agonist PDGF-BB reduced mural cell loss, vascular pathology, and epileptiform activity [15,57,58]. The gene discussed is PDGFRB; the disease is epilepsy.